Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?

NCT ID NCT07739459

Not yet recruiting Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This phase II trial is testing whether a planned dose reduction of the targeted therapy zanubrutinib can maintain control of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) while reducing long-term side effects in patients aged 80 and older who have not yet received treatment. The study will track how long the disease stays under control and how many patients need to stop treatment permanently. The goal is to find a dosing strategy that balances effectiveness with tolerability for a particularly vulnerable age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (Brukinsa), an oral BTK inhibitor
What this could lead to: If successful, this could show that a lower maintenance dose of zanubrutinib keeps CLL controlled while being gentler for very elderly patients, potentially improving quality of life.
What could go wrong: This is a phase II trial with a modest number of participants, so results may not be definitive. Reducing the dose could also reduce effectiveness, and side effects may still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Centre Henri Becquerel

Rouen, 76038, France
Centre Leon Berard

Lyon, 69373, France
Ch D'Avignon - Hopital Henri Duffaut

Avignon, 84000, France
Ch Du Mans-Centre de Cancerologie de La Sarthe

Le Mans, 72000, France
Ch Rene Dubos

Cergy-Pontoise, 95303, France
Ch Sud Francilien

Corbeil-Essonnes, 91106, France
Ch Victor Dupouy

Argenteuil, 95107, France
Ch de La Cote Basque

Bayonne, 64109, France
Ch de Versailles - Hopital Andre Mignot

Le Chesnay, 78157, France
Chru Nancy - Hôpital Brabois

Vandœuvre-lès-Nancy, 54511, France
Chu Lyon-Sud

Lyon, Pierre Bénite, 69310, France
Chu Orleans

Orléans, 45067, France
Chu de Clermont-Ferrand

Estaing, - SITE ESTAING, France
Chu de Grenoble

Grenoble, 38700, France
Hopital Saint Vincent-de-Paul

Lille, 59020, France
Institut Bergonie

Bordeaux, 33076, France
Iuct Oncopole

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.